

Supplementary Online Content

Olivier T, Haslam A, Tuia J, Prasad V. Eligibility by Race and Ethnicity for Human Leukocyte Antigen–Based therapeutics. *JAMA Netw Open*. 2023;6(10):e2338612. doi:10.1001/jamanetworkopen.2023.38612

eTable. Tumor Types, According to the Mechanism of Action Under Investigation, in Selected Trials Studying an Anticancer Therapy (n=258)


eFigure. Flowchart of the Trial Selection Process and Reasons for Exclusion

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Tumor Types, According to the Mechanism of Action Under Investigation, in Selected Trials Studying an Anticancer Therapy (n=258)

	Cellular Therapy	Fusion Protein	Other	Vaccine Therapy	Total
	(N=71)	(N=8)	(N=3)	(N=176)	(N=258)
<u>Tumor type</u>					
Central Nervous System	1 (1.4%)	0 (0%)	0 (0%)	16 (9.1%)	17 (6.6%)
Cervical Cancer	1 (1.4%)	0 (0%)	0 (0%)	0 (0%)	1 (0.4%)
Esophageal Cancer	2 (2.8%)	0 (0%)	0 (0%)	4 (2.3%)	6 (2.3%)
Head and Neck	3 (4.2%)	1 (12.5%)	0 (0%)	1 (0.6%)	5 (1.9%)
Heme Malignancies	9 (12.7%)	0 (0%)	1 (33.3%)	12 (6.8%)	22 (8.5%)
Kidney Cancer	1 (1.4%)	0 (0%)	0 (0%)	2 (1.1%)	3 (1.2%)
Liver Cancer	4 (5.6%)	0 (0%)	0 (0%)	2 (1.1%)	6 (2.3%)
Many Tumor Types	25 (35.2%)	4 (50.0%)	0 (0%)	14 (8.0%)	43 (16.7%)
Melanoma	10 (14.1%)	3 (37.5%)	0 (0%)	54 (30.7%)	67 (26.0%)
Non-Small Cell Lung Cancer	2 (2.8%)	0 (0%)	2 (66.7%)	13 (7.4%)	17 (6.6%)
Other	3 (4.2%)	0 (0%)	0 (0%)	1 (0.6%)	4 (1.6%)
Ovarian Cancer	4 (5.6%)	0 (0%)	0 (0%)	5 (2.8%)	9 (3.5%)
Pancreatic Cancer	1 (1.4%)	0 (0%)	0 (0%)	6 (3.4%)	7 (2.7%)
Sarcoma	5 (7.0%)	0 (0%)	0 (0%)	0 (0%)	5 (1.9%)
Bladder Cancer	0 (0%)	0 (0%)	0 (0%)	1 (0.6%)	1 (0.4%)
Breast Cancer	0 (0%)	0 (0%)	0 (0%)	23 (13.1%)	23 (8.9%)
Colorectal Carcinoma	0 (0%)	0 (0%)	0 (0%)	5 (2.8%)	5 (1.9%)
Gastric Cancer	0 (0%)	0 (0%)	0 (0%)	4 (2.3%)	4 (1.6%)
Prostate Cancer	0 (0%)	0 (0%)	0 (0%)	11 (6.3%)	11 (4.3%)
Renal Cell Carcinoma	0 (0%)	0 (0%)	0 (0%)	1 (0.6%)	1 (0.4%)
Small Cell Lung Cancer	0 (0%)	0 (0%)	0 (0%)	1 (0.6%)	1 (0.4%)

eFigure. Flowchart of the Trial Selection Process and Reasons for Exclusion



* Among those: 34 trials studied HLA as a biomarker, 2 referred to HLA as hyaluronic acid, and 3 others had no relation with classical HLA subtypes.